Christopher P Dillon

Years Active: 2016-2021
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Kristen Jensen-Pergakes, John Tatlock, Karen A Maegley, Indrawan J McAlpine, Michele A McTigue, Tao Xie, Christopher P Dillon, Yuli Wang, Shinji Yamazaki, Noah Spiegel, Manli Shi, Amy Nemeth, Natalie Miller, Eleanore Hendrickson, Hieu Lam, John Sherrill, Chi-Yeh Chung, Elizabeth A McMillan, Shannon Karlicek Bryant, Prakash Palde, John Braganza, Alexei Brooun, Ya-Li Deng, Vesta Goshtasbi, Susan E Kephart, Robert A Kumpf, Wei Liu, Ryan L Patman, Eugene Rui, Stephanie Scales, Michelle Tran-Dube, Fen Wang, Martin Wythes, Thomas A Paul
SAM Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. Molecular cancer therapeutics (2021)
Amir A Al-Khami, Sawsan Youssef, Yasmina Abdiche, HoangKim Nguyen, Jeffrey Chou, Christopher R Kimberlin, Sherman M Chin, Cris Kamperschroer, Bart Jessen, Brent Kern, Natalija Budimir, Christopher P Dillon, Allison Xu, Jerry D Clark, Eugenia Kraynov, Arvind Rajpal, John C Lin, Shahram Salek-Ardakani
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Molecular cancer therapeutics 19 (10) (2020)
Lance W Peterson, Naomi H Philip, Christopher P Dillon, John Bertin, Peter J Gough, Douglas R Green, Igor E Brodsky
Cell-Extrinsic TNF Collaborates with TRIF Signaling To Promote Yersinia-Induced Apoptosis. Journal of immunology (Baltimore, Md. : 1950) 197 (10) (2016)

Christopher P Dillon.css-eqlu8i{font-size:small;padding-left:4px;}